UBS lowered the firm’s price target on ResMed (RMD) to $285 from $290 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed price target lowered to $250 from $265 at Mizuho
- ResMed price target lowered to $248 from $260 at Piper Sandler
- ResMed price target raised to $255 from $247 at RBC Capital
- ResMed: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- ResMed price target raised to $274 from $269 at KeyBanc